trending Market Intelligence /marketintelligence/en/news-insights/trending/99hearfzjnci7jhjxlsl5q2 content esgSubNav
In This List

Otonomy's treatment for ear inflammation, infection secures US FDA approval

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Otonomy's treatment for ear inflammation, infection secures US FDA approval

San Diego-based Otonomy Inc. said the U.S. Food and Drug Administration has approved Otiprio for treating a type of ear inflammation and infection in certain patients.

The drug is the first single-dose antibacterial approved by the FDA to treat the infection and inflammation of the external ear canal typically caused by a bacterial infection known as swimmer's ear, or acute otitis externa.

Otiprio has been approved by the regulatory agency to treat the condition in patients 6 months and older caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.